These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 34425763

  • 1. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
    Patti F, Penaherrera JN, Zieger L, Wicklein EM.
    BMC Neurol; 2021 Aug 23; 21(1):324. PubMed ID: 34425763
    [Abstract] [Full Text] [Related]

  • 2. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL, Scott LJ.
    CNS Drugs; 2004 Aug 23; 18(8):521-46. PubMed ID: 15182221
    [Abstract] [Full Text] [Related]

  • 3. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL, Scott LJ.
    BioDrugs; 2004 Aug 23; 18(5):343-7. PubMed ID: 15377176
    [Abstract] [Full Text] [Related]

  • 4. Interferon-β-1b: a review of its use in multiple sclerosis.
    Plosker GL.
    CNS Drugs; 2011 Jan 23; 25(1):67-88. PubMed ID: 21128695
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S, Rahimi R, Abdollahi M.
    Clin Ther; 2010 Oct 23; 32(11):1871-88. PubMed ID: 21095482
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study.
    Chisari CG, Aguglia U, Amato MP, Bergamaschi R, Bertolotto A, Bonavita S, Morra VB, Cavalla P, Cocco E, Conte A, Cottone S, De Luca G, Di Sapio A, Filippi M, Gallo A, Gasperini C, Granella F, Lus G, Maimone D, Maniscalco GT, Marfia G, Moiola L, Paolicelli D, Pesci I, Ragonese P, Rovaris M, Salemi G, Solaro C, Totaro R, Trojano M, Vianello M, Zaffaroni M, Lepore V, Patti F, Italian MS Register Study Group.
    Neurotherapeutics; 2024 Jul 23; 21(4):e00363. PubMed ID: 38714462
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
    Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H, European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board, North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board.
    Neurology; 2004 Nov 23; 63(10):1779-87. PubMed ID: 15557490
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC, Russell M, Lily O, Ford HL.
    Mult Scler Relat Disord; 2020 Sep 23; 44():102330. PubMed ID: 32599468
    [Abstract] [Full Text] [Related]

  • 18. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
    Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S.
    Eur J Neurol; 2010 May 23; 17(5):672-6. PubMed ID: 20039942
    [Abstract] [Full Text] [Related]

  • 19. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP.
    Eur J Neurol; 2001 Mar 23; 8(2):141-8. PubMed ID: 11284992
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.